Call To Abolish US/EU Biotech Barriers

5 February 1996

US and European Union trade officials should find ways to dismantle regulatory barriers to trade in biotechnology products, EU Trade Commissioner Sir Leon Brittan has told the European parliament's external economic relations committee.

This trade could provide huge economic opportunities and should not be allowed "to stultify by the creation of non-tariff barriers," he said. The two sides should "discuss whether we have common regulation or some other way of ensuring consistency," and should be "conscious of the need to stimulate industry....to prevent regulatory instruments becoming barriers to trade." The USA and EU are at odds over how to regulate the industry, with the EU more cautious on what to allow.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight